Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) had its target price reduced by HC Wainwright from $12.00 to $5.00 in a ...

Inovio Pharmaceuticals (NASDAQ:INO – Free Report) had its price objective cut by Royal Bank of Canada from $7.00 to $6.00 in ...

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

Shares of Inovio Pharmaceuticals Inc. INO slipped 2.91% to $4.01 Tuesday, on what proved to be an all-around favorable ...

H.C. Wainwright analyst Ram Selvaraju has reiterated their neutral stance on INO stock, giving a Hold rating on November 14.Don't Miss our ...

Inovio Pharmaceuticals (INO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Roy ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

Inovalis Real Estate Investment Trust (the "REIT") (TSX: INO.UN) today announced the signing of an exchange contract for the sale of the Sablière property to a third party for €18.2 million ($26.4 ...

Inovio Pharmaceuticals (NASDAQ: INO) Q3 2024 Earnings Call Nov 14, 2024, 4:30 p.m. ET ...

Confidence in INO-3107's market potential was expressed ... article's mention of less than one year of cash runway. The tip that the "stock has taken a big hit over the last six months" is ...

INO) has entered into a sales agreement with Oppenheimer & Co. Inc. The agreement, which allows for the potential sale of common stock at the company's discretion, could total up to $60 million.